Literature DB >> 17361501

What is the cost to employers of direct medical care for chronic obstructive pulmonary disease?

Tursynbek Nurmagambetov1, Adam Atherly, Seymour Williams, Fernando Holguin, David M Mannino, Stephen C Redd.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in the United States. In 2000, an estimated 10.5 million people had COPD, of which more than 7.2 million were from the under-age 65 employed population. The prevalence of COPD in the workforce population was substantial with 46.5% of current employment among adults having the disease. However, the cost burden in the employed population is unknown. We examined COPD prevalence and costs in a large employment-based population. Using claims data from 1999 to 2003, we estimated the cost associated with COPD-related hospitalizations, emergency department visits, outpatient services, and prescription drug use. Per patient use of hospital care for COPD decreased during 1999 through 2003, including a decrease in the number of hospital admissions (from 0.10 in 1999 to 0.04 in 2003) and in the length of stay in hospitals (from 0.53 in 1999 to 0.17 in 2003). The number of outpatient visits, however, increased from 3.45 in 1999 to 3.80 in 2003. COPD-related per patient total medical costs decreased from $1460 in 1999 to $1138 in 2003 largely because of a decrease in the cost of hospitalizations for COPD. In contrast, mean per patient expenditures for outpatient services increased over the same period from $243 in 1999 to $295 in 2003. The cost of COPD to employers is high, but the cost could be reduced by programs aimed at preventing new cases of COPD, reducing hospitalizations, and providing more outpatient services to COPD patients.

Entities:  

Mesh:

Year:  2006        PMID: 17361501     DOI: 10.1080/15412550600977320

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  7 in total

1.  Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients.

Authors:  Anand A Dalal; Meaghan St Charles; Hans V Petersen; Melissa H Roberts; Christopher M Blanchette; Kathy Manavi-Zieverink
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

2.  The costs of hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Sevket Ozkaya; Serhat Findik; Atilla Guven Atici
Journal:  Clinicoecon Outcomes Res       Date:  2011-01-17

3.  Birmingham COPD Cohort: a cross-sectional analysis of the factors associated with the likelihood of being in paid employment among people with COPD.

Authors:  Kiran K Rai; Rachel E Jordan; W Stanley Siebert; Steven S Sadhra; David A Fitzmaurice; Alice J Sitch; Jon G Ayres; Peymané Adab
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-01-11

4.  Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study.

Authors:  Florian Kirsch; Anja Schramm; Larissa Schwarzkopf; Johanna I Lutter; Boglárka Szentes; Manuel Huber; Reiner Leidl
Journal:  Respir Res       Date:  2019-10-10

5.  Does Chronic Obstructive Pulmonary Disease Affect Workers' Health?

Authors:  Li-Peng Yao; Ran Tao
Journal:  Front Public Health       Date:  2021-07-05

6.  Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial.

Authors:  Dennis L Kelleher; Rashmi S Mehta; Bernadette M Jean-Francois; Andrew F Preece; James Blowers; Glenn D Crater; Paul Thomas
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

Review 7.  Exacerbation rate, health status and mortality in COPD--a review of potential interventions.

Authors:  Terence A R Seemungal; John R Hurst; Jadwiga A Wedzicha
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-06-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.